Trial Profile
Protocol ATI001-102 Expansion Substudy: Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs INXN 2001 (Primary) ; Veledimex (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Alaunos Therapeutics
- 21 Sep 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 29 May 2020 Results published in the ZIOPHARM Oncology media release.